(NASDAQ: OBIO) Orchestra Biomed Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.
Orchestra Biomed Holdings's earnings in 2025 is -$61,024,000.On average, 5 Wall Street analysts forecast OBIO's earnings for 2025 to be -$75,475,649, with the lowest OBIO earnings forecast at -$80,073,150, and the highest OBIO earnings forecast at -$72,027,523. On average, 3 Wall Street analysts forecast OBIO's earnings for 2026 to be -$66,280,646, with the lowest OBIO earnings forecast at -$70,495,022, and the highest OBIO earnings forecast at -$60,916,894.
In 2027, OBIO is forecast to generate -$65,514,396 in earnings, with the lowest earnings forecast at -$65,514,396 and the highest earnings forecast at -$65,514,396.